Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress

Samsung Bioepis Co announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).